Table 2.
Trends in extranodal diffuse large B-cell lymphoma incidence rates (1973–2015): the SEER-9 registry database.
| Trend | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall (1973–2015) | 1 | 2 | 3 | 4 | 5 | 6 | |||||||
| APC (95% CI) | Year | APC (95% CI) | Year | APC (95% CI) | Year | APC (95% CI) | Year | APC (95% CI) | Year | APC (95% CI) | Year | APC (95% CI) | |
| Overall | 1.6 (0.4 to 2.8) | 1973–1979 | −2.2 (−5.9 to 1.6) | 1979–1985 | 10.3 (6.0–14.8) | 1985–1993 | 5.2 (3.3 to 7.1) | 1993–1996 | −4.3 (−14.6 to 7.2) | 1996–2003 | 3.3 (1.4 to 5.2) | 2003–2015 | −2.2 (−2.8 to −1.6) |
| Age, y | |||||||||||||
| ≤14 | 1.5 (0.2 to 2.8) | 1973–2015 | 1.5 (0.2 to 2.8) | ||||||||||
| 15–39 | 4.1 (2.9 to 5.2) | 1973–1991 | 11.4 (8.8 to 14.1) | 1991–2015 | −1.1 (−2.0 to −0.3) | ||||||||
| 40–64 | 2.1 (−1.4 to 5.7) | 1973–1975 | 22.4 (−18.9 to 84.5) | 1975–1978 | −12.2 (−39.2 to 26.8) | 1978–1989 | 8.6 (6.0 to 11.3) | 1989–2007 | 0.6 (−0.2 to 1.3) | 2007–2010 | −7.7 (−23.6 to 11.5) | 2010–2015 | 2.0 (−2.3 to 6.5) |
| 65–85+ | 1.7 (0.6 to 2.8) | 1973–1978 | −2.5 (−8.6 to 3.9) | 1978–1991 | 7.3 (6.0 to 8.6) | 1991–1996 | −1.5 (−6.3 to 3.5) | 1996–2003 | 4.0 (1.6 to 6.5) | 2003–2015 | −2.3 (−3.0 to −1.6) | ||
| Sex | |||||||||||||
| Male | 1.9 (0.8 to 3.0) | 1973–1978 | −2.7 (−10.1 to 5.2) | 1978–1991 | 8.2 (6.6 to 9.8) | 1991–2005 | 0.5 (−0.4 to 1.4) | 2005–2015 | −1.8 (−2.9 to −0.7) | ||||
| Female | 1.4 (−0.5 to 3.4) | 1973–1981 | −0.3 (−4.9 to 4.6) | 1981–1985 | 13.5 (−4.5 to 34.8) | 1985–2004 | 2.1 (1.3 to 3.0) | 2004–2015 | −2.6 (−4.0 to −1.1) | ||||
| Race | |||||||||||||
| White | 1.7 (0.7 to 2.6) | 1973–1980 | −0.5 (−4.1 to 3.3) | 1980–1990 | 9.0 (7.0 to 11.1) | 1990–1997 | −0.7 (−3.3 to 1.9) | 1997–2003 | 3.5 (0.3 to 6.8) | 2003–2015 | −2.4 (−3.2 to −1.6) | ||
| Black | 1.1 (−0.2 to 2.4) | 1973–2005 | 2.9 (1.6 to 4.2) | 2005–2015 | −4.3 (−8.0 to −0.4) | ||||||||
| Other | 2.5 (1.1 to 3.9) | 1973–1993 | 5.7 (2.9 to 8.6) | 1993–2015 | −0.4 (−1.4 to 0.7) | ||||||||
| Ann Arbor Stage | |||||||||||||
| I/II | 0.9 (0.1 to 1.7) | 1983–1990 | 5.7 (2.7 to 8.8) | 1990–2003 | 1.7 (0.8 to 2.7) | 2003–2015 | −2.8 (−3.7 to −1.9) | ||||||
| III/IV | 2.5 (1.0 to 4.1) | 1983–1990 | 8.7 (2.6 to 15.1) | 1990–2007 | 1.9 (0.8 to 3.1) | 2007–2015 | −1.3 (−4.2 to 1.6) | ||||||
| Unknown | −1.8 (−2.9 to −0.6) | 1983–2015 | −1.8 (−2.9 to −0.6) | ||||||||||
| Site | |||||||||||||
| Head/Neck | 2.3 (1.2 to 3.4) | 1973–1986 | 7.4 (4.4 to 10.5) | 1986–2003 | 1.7 (0.4 to 3.0) | 2003–2015 | −2.1 (−3.7 to −0.4) | ||||||
| Skin and soft tissue | 2.3 (1.2 to 3.3) | 1973–2000 | 5.5 (4.1 to 6.8) | 2000–2015 | −3.2 (−5.1 to −1.4) | ||||||||
| Gastrointestinal tract | 0.1 (−1.1 to 1.4) | 1973–1978 | −4.6 (−12.2 to 3.6) | 1978–1987 | 9.3 (5.8 to 12.9) | 1987–2005 | −0.3 (−1.0 to 0.5) | 2005-2015 | −4.5 (−6.1 to −2.8) | ||||
| Genitourinary tract | 2.3 (1.2 to 3.3) | 1973–2003 | 4.3 (3.2 to 5.5) | 2003–2015 | −2.7 (−5.2 to −0.1) | ||||||||
| Skeletal tissue | 2.0 (−1.4 to 5.5) | 1973–1981 | −10.2 (−21.7 to 2.9) | 1981–1991 | 13.7 (3.6 to 24.7) | 1991–2015 | 1.7 (0.4 to 3.0) | ||||||
| Respiratory system | 4.2 (0.4 to 8.1) | 1973–1985 | 2.3 (-5.8 to 11.1) | 1985–1991 | 24.1 (1.0 to 52.6) | 1991–2015 | 0.7 (−0.5 to 1.8) | ||||||
| Hematologic system | 8.2 (6.0 to 10.5) | 1974–1992 | 13.3 (8.1 to 18.7) | 1992–2015 | 4.4 (3.1 to 5.7) | ||||||||
| Liver/pancreas | 4.8 (3.1 to 6.6) | 1974–2001 | 8.3 (5.8 to 10.9) | 2001–2015 | −1.6 (−4.1 to 1.0) | ||||||||
| Breast tissue | 2.1 (1.2 to 3.1) | 1973–2015 | 2.1 (1.2 to 3.1) | ||||||||||
| Other | −0.5 (−7.1 to 6.7) | 1973–1982 | −18.4 (−29.1 to −6.1) | 1982–1986 | 36.9 (−30.6 to 169.8) | 1986–2015 | 1.3 (−0.0 to 2.7) | ||||||